MedTrace Logo

Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus

NCT03052400 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-05-18

Study results available
· View outcomes & findings →

Summary

Randomized, double blind, placebo-controlled clinical trial examining the efficacy and safety of mifepristone 600 mg daily in male subjects with type 2 diabetes mellitus, not associated with Cushing's syndrome

Conditions

Interventions

DRUG

Mifepristone 600 mg daily

Glucocorticoid receptor antagonist

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • Charles Drew University of Medicine and Science

    lead OTHER

Principal Investigators

  • Stanley H Hsia, MD · Charles Drew University of Medicine and Science

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-03
Primary Completion
2021-03-31
Completion
2021-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03052400 on ClinicalTrials.gov